Abstract
Purpose: To investigate the clinical implications of cysteine-rich angiogenic inducer 61 (CYR61) in Graves’ orbitopathy (GO). Methods: Sera from 52 GO patients, 23 Graves’ disease (GD) patients, and 20 healthy controls, and orbital fat tissue samples from 12 of 52 GO patients and 8 control subjects were included for analysis. Concentrations of CYR61 were measured from sera with an enzyme-linked immunosorbent assay, and CYR61 mRNA expression levels were evaluated from orbital fat tissue with polymerase chain reaction. Results: Serum CYR61 levels were higher in GO patients than in controls (p = 0.001). Patients with active GO showed higher CYR61 levels than those with inactive GO (p < 0.001) or GD (p = 0.004). Expression of CYR61 mRNA was 7.4-fold higher in patients with GO than in healthy controls (p < 0.001). Conclusions: CYR61 could be an adjuvant biomarker associated with the inflammatory activity of GO.
| Original language | English |
|---|---|
| Pages (from-to) | 1094-1100 |
| Number of pages | 7 |
| Journal | Ocular Immunology and Inflammation |
| Volume | 26 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2018 Oct 3 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Ophthalmology
Cite this
}
Serum CYR61 Is Associated with Disease Activity in Graves’ Orbitopathy. / Woo, Young Jun; Seo, Yuri; Kim, Jin Joo; Kim, Ji Won; Park, Yil; Yoon, Jin Sook.
In: Ocular Immunology and Inflammation, Vol. 26, No. 7, 03.10.2018, p. 1094-1100.Research output: Contribution to journal › Article
TY - JOUR
T1 - Serum CYR61 Is Associated with Disease Activity in Graves’ Orbitopathy
AU - Woo, Young Jun
AU - Seo, Yuri
AU - Kim, Jin Joo
AU - Kim, Ji Won
AU - Park, Yil
AU - Yoon, Jin Sook
PY - 2018/10/3
Y1 - 2018/10/3
N2 - Purpose: To investigate the clinical implications of cysteine-rich angiogenic inducer 61 (CYR61) in Graves’ orbitopathy (GO). Methods: Sera from 52 GO patients, 23 Graves’ disease (GD) patients, and 20 healthy controls, and orbital fat tissue samples from 12 of 52 GO patients and 8 control subjects were included for analysis. Concentrations of CYR61 were measured from sera with an enzyme-linked immunosorbent assay, and CYR61 mRNA expression levels were evaluated from orbital fat tissue with polymerase chain reaction. Results: Serum CYR61 levels were higher in GO patients than in controls (p = 0.001). Patients with active GO showed higher CYR61 levels than those with inactive GO (p < 0.001) or GD (p = 0.004). Expression of CYR61 mRNA was 7.4-fold higher in patients with GO than in healthy controls (p < 0.001). Conclusions: CYR61 could be an adjuvant biomarker associated with the inflammatory activity of GO.
AB - Purpose: To investigate the clinical implications of cysteine-rich angiogenic inducer 61 (CYR61) in Graves’ orbitopathy (GO). Methods: Sera from 52 GO patients, 23 Graves’ disease (GD) patients, and 20 healthy controls, and orbital fat tissue samples from 12 of 52 GO patients and 8 control subjects were included for analysis. Concentrations of CYR61 were measured from sera with an enzyme-linked immunosorbent assay, and CYR61 mRNA expression levels were evaluated from orbital fat tissue with polymerase chain reaction. Results: Serum CYR61 levels were higher in GO patients than in controls (p = 0.001). Patients with active GO showed higher CYR61 levels than those with inactive GO (p < 0.001) or GD (p = 0.004). Expression of CYR61 mRNA was 7.4-fold higher in patients with GO than in healthy controls (p < 0.001). Conclusions: CYR61 could be an adjuvant biomarker associated with the inflammatory activity of GO.
UR - http://www.scopus.com/inward/record.url?scp=85019701889&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019701889&partnerID=8YFLogxK
U2 - 10.1080/09273948.2017.1319960
DO - 10.1080/09273948.2017.1319960
M3 - Article
C2 - 28548552
AN - SCOPUS:85019701889
VL - 26
SP - 1094
EP - 1100
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
SN - 0927-3948
IS - 7
ER -